Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDLandos Biopharma, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.88 | -$0.88 | -$0.88 |
| Q2 2024 | 1 | -$0.80 | -$0.45 | -$0.63 |
| Q3 2024 | 1 | -$0.48 | -$0.48 | -$0.48 |
| Q4 2024 | 1 | -$0.53 | -$0.53 | -$0.53 |
| Q1 2025 | 1 | -$0.67 | -$0.67 | -$0.67 |
| Q2 2025 | 1 | -$0.52 | -$0.52 | -$0.52 |
| Q3 2025 | 1 | -$0.46 | -$0.46 | -$0.46 |
| Q4 2025 | 1 | -$0.50 | -$0.50 | -$0.50 |
Landos Biopharma, Inc. Earnings Date And Information
Landos Biopharma, Inc. last posted its earnings results on Thursday, May 9th, 2024. The company reported $-1.43 earnings per share for the quarter, missing analysts' consensus estimates of $-1 by $0.43. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Landos Biopharma, Inc. has generated $-4 earnings per share over the last year ($-3.5 diluted earnings per share) and currently has a price-to-earnings ratio of -5.74. Landos Biopharma, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 7th, 2024 based on prior year's report dates.
Landos Biopharma, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 05/09/2024 | Q1 2024 | -$1.00 | -$1.43 | -0.43 | $0 | $0 |
| 03/21/2024 | Q4 2023 | -$0.91 | -$0.99 | -0.08 | $0 | |
| 11/09/2023 | Q3 2023 | -$0.79 | -$0.94 | -0.15 | $0 | |
| 08/09/2023 | Q2 2023 | -$1.10 | -$0.63 | 0.47 | $0 | |
| 05/12/2023 | Q1 2023 | -$1.00 | -$0.86 | 0.14 | $0 | |
| 03/23/2023 | Q4 2022 | -$1.50 | -$0.96 | 0.54 | $0 | |
| 11/10/2022 | Q3 2022 | -$2.90 | -$1.98 | 0.92 | $0 | |
| 08/11/2022 | Q2 2022 | -$3.70 | -$2.81 | 0.89 | $0 | |
| 05/12/2022 | Q1 2022 | -$3.70 | -$3.67 | 0.03 | $0 | |
| 03/24/2022 | Q4 2021 | -$0.33 | -$5.20 | -4.87 | $-18,000,000 | |
| 11/15/2021 | Q3 2021 | -$4.40 | -$3.20 | 1.2 | $0 | |
| 07/29/2021 | Q2 2021 | -$1.40 | $1.20 | 2.6 | $18.00 M | |
| 05/17/2021 | Q1 2021 | -$0.37 | -$3.80 | -3.43 | $0 | |
| 03/31/2021 | Q4 2020 | -$2.90 | $0 | |||
| 09/29/2020 | Q3 2020 | -$2.52 | $0 | |||
| 06/29/2020 | Q2 2020 | -$1.46 | $0 | |||
| 03/30/2020 | Q1 2020 | -$1.78 | $0 | |||
| 12/30/2019 | Q4 2019 | -$1.08 | $0 |
Landos Biopharma, Inc. Earnings: FAQ's
When is Landos Biopharma, Inc.'s earnings date?
Landos Biopharma, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 7th, 2024 based off last year's report dates.
How can I listen to Landos Biopharma, Inc.'s earnings conference
call?
The conference call for Landos Biopharma, Inc.'s latest earnings report can be listened to online.
How can I read Landos Biopharma, Inc.'s conference call transcript?
The conference call transcript for Landos Biopharma, Inc.'s latest earnings report can be read online.
How much profit does Landos Biopharma, Inc. generate each year?
Landos Biopharma, Inc. (:LABP) has a recorded net income of $0. Landos Biopharma, Inc. has generated $-3.5 earnings per share over the last four quarters.
What is Landos Biopharma, Inc.'s price-to-earnings ratio?
Landos Biopharma, Inc. (:LABP) has a price-to-earnings ratio of -5.74 and price/earnings-to-growth ratio is 0.34.